Myeloid Leukemia News and Research RSS Feed - Myeloid Leukemia News and Research

Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.
Study of genetic mutations could lead to optimized treatment plans for aplastic anemia patients

Study of genetic mutations could lead to optimized treatment plans for aplastic anemia patients

Scientists have identified a group of genetic mutations in patients with aplastic anemia, which likely will help doctors optimize treatment for this rare and deadly blood condition. The study, appearing in the New England Journal of Medicine, could lead to tailor-made treatment plans for aplastic anemia patients as part of the emerging precision medicine movement. [More]
Current treatments for blood cancer priced too high to be considered cost-effective, new analysis finds

Current treatments for blood cancer priced too high to be considered cost-effective, new analysis finds

The costs associated with cancer drug prices have risen dramatically over the past 15 years, which is of concern to many top oncologists. In a new analysis, researchers at The University of Texas MD Anderson Cancer Center concluded the majority of existing treatments for hematologic, or blood, cancers are currently priced too high to be considered cost-effective in the United States. [More]
ExCellThera's stem cell expansion approach may benefit AML patients undergoing transplants

ExCellThera's stem cell expansion approach may benefit AML patients undergoing transplants

Patients suffering from acute myeloid leukemia, who require stem cell transplantation as part of their treatment,may now benefit from a new best-in-class process that improves the viability and success of cord blood stem cell transplantation. [More]
Molecules derived from avocados could help combat acute myeloid leukemia

Molecules derived from avocados could help combat acute myeloid leukemia

Rich, creamy, nutritious and now cancer fighting. New research reveals that molecules derived from avocados could be effective in treating a form of cancer. [More]
Combination of tosedostat and LDAC results in overall response rate of 54% in elderly patients with AML

Combination of tosedostat and LDAC results in overall response rate of 54% in elderly patients with AML

CTI BioPharma Corp. today announced findings from an investigator-sponsored Phase 2 trial in patients with either primary (de novo) acute myeloid leukemia (AML) or AML that has evolved from myelodysplastic syndrome (MDS). Results showed the combination of tosedostat with low dose cytarabine/Ara-C (LDAC) resulted in an overall response rate (ORR) of 54 percent in elderly patients with AML – with 45 percent of patients achieving durable complete responses (CR). [More]
NeoGenomics announces launch of new NeoLAB assays to diagnose hematologic diseases

NeoGenomics announces launch of new NeoLAB assays to diagnose hematologic diseases

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today the launch of its first twelve tests in a new line of "liquid biopsy" or NeoLAB assays using next generation sequencing and other advanced molecular technologies. [More]
Researchers identify potential treatment option for childhood leukemia

Researchers identify potential treatment option for childhood leukemia

Researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center are reporting a potentially important discovery in the battle against one of the most devastating forms of leukemia that accounts for as many as one in five children with a particularly aggressive form of the disease relapsing within a decade. [More]
US cancer physicians explore new approach to help older patients undergoing hematopoietic stem cell transplant

US cancer physicians explore new approach to help older patients undergoing hematopoietic stem cell transplant

When stem cell transplant first became part of standard treatment for certain cancers and blood diseases twenty years ago, individuals older than 60 were rarely considered for the procedure. [More]
Researchers report new way to treat T-cell acute lymphoblastic leukemia

Researchers report new way to treat T-cell acute lymphoblastic leukemia

Researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center are reporting a potentially important discovery in the battle against one of the most devastating forms of leukemia that accounts for as many as one in five children with a particularly aggressive form of the disease relapsing within a decade. [More]
CASI files application with CFDA to conduct ENMD-2076 Phase 2 trial in fibrolamellar carcinoma patients

CASI files application with CFDA to conduct ENMD-2076 Phase 2 trial in fibrolamellar carcinoma patients

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announced today that it has filed an application with China's Food and Drug Administration to conduct a Phase 2 clinical trial in fibrolamellar carcinoma (FLC) patients in China for its proprietary drug candidate, ENMD-2076. [More]
Poster related to Cantex's lead compound CX-01 presented at ASCO 2015

Poster related to Cantex's lead compound CX-01 presented at ASCO 2015

Cantex Pharmaceuticals, a clinical stage biopharmaceutical company developing medications that block critical mechanisms by which cancer spreads and resists treatment, today announced Tibor Kovacsovics, M.D., Medical Director for the Inpatient Service of the Division of Hematology and Hematologic Malignancies and Director of Hematologic Malignancy Clinical Research at Huntsman Cancer Institute presented a poster related to Cantex's lead compound, CX-01, at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO). [More]
Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185 data presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, and the Congress of the European Hematology Association (EHA), June 11-14. [More]
Preliminary data from ASP2215 Phase 1/2 trial in AML patients presented at ASCO annual meeting

Preliminary data from ASP2215 Phase 1/2 trial in AML patients presented at ASCO annual meeting

Astellas Pharma Inc. today announced that preliminary data from a Phase 1/2 trial on the safety, tolerability and efficacy of ASP2215, a selective inhibitor of FLT3/AXL, in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) were presented during an oral abstract session at the American Society of Clinical Oncology's annual meeting in Chicago. [More]
Over 700 Chinese patients with acute myeloid leukemia undergo Microtransplantation treatment

Over 700 Chinese patients with acute myeloid leukemia undergo Microtransplantation treatment

According to Dr. Huisheng Ai's team, founder of Microtransplantation regimen mainly for Acute Myeloid Leukemia, over 700 patients have undergone this therapy since its emergence in 2002. Based at MST International Clinic for Leukemia in the 307th Hospital of Chinese People's Liberation Army in Beijing, about 40 hematology centers covering all main hospitals in 32 provinces of mainland China have adopted Microtransplantation regimen. [More]
Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

CTI BioPharma Corp. and Baxter International's Bioscience business today announced data from PERSIST-1 – a randomized Phase 3 registration-directed trial examining pacritinib for the treatment of myelofibrosis – in a late-breaking oral session at the 51st Annual Meeting of the American Society of Clinical Oncology, May 29-June 2, 2015 in Chicago, Ill. [More]
Researchers discover how and where chromosome fragile sites occur in human DNA

Researchers discover how and where chromosome fragile sites occur in human DNA

Using a novel method they developed to map chromosome breaks in a model organism, the budding yeast, Wenyi Feng, Ph.D., of Upstate Medical University and her colleagues have discovered new information as to how and where chromosome fragile sites can occur in human DNA. These sites are frequently observed in cancer cells and are responsible for causing genomic rearrangements. [More]
Researchers identify promising combination strategy for treating glioblastomas

Researchers identify promising combination strategy for treating glioblastomas

Therapies that specifically target mutations in a person's cancer have been much-heralded in recent years, yet cancer cells often find a way around them. To address this, researchers at University of California, San Diego School of Medicine and Moores Cancer Center identified a promising combinatorial approach to treating glioblastomas, the most common form of primary brain cancer. [More]
ITIM-containing receptor crucial for development of acute myeloid leukemia

ITIM-containing receptor crucial for development of acute myeloid leukemia

UT Southwestern Medical Center scientists have discovered that a certain class of receptors that inhibit immune response are crucial for the development of acute myeloid leukemia (AML), the most common acute leukemia affecting adults. [More]
Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

CTI BioPharma Corp. and Baxter International Inc. today announced that data from the randomized Phase 3 PERSIST-1 trial evaluating the investigational agent pacritinib in patients with myelofibrosis will be highlighted in a late-breaking oral presentation at the upcoming American Society of Clinical Oncology 2015 Meeting (May 29-June 2, 2015 in Chicago, Ill). [More]
SELLAS inks exclusive global collaboration, license agreement with TrojanTec

SELLAS inks exclusive global collaboration, license agreement with TrojanTec

SELLAS Life Sciences Group, a Swiss based, development-stage biopharmaceutical company with its main focus in developing innovative products for the treatment of various indications in Oncology and the Central Nervous System, today announced that it has signed an exclusive global collaboration and license agreement with TrojanTec Ltd, a UK-based Discovery Research and Development Company affiliated with Imperial College London, UK, for the development, marketing and commercialization of the innovative and proprietary TR-1 cancer therapeutic technology and drug. [More]
Advertisement